Recently, CMTM4 and CMTM6 are identified as PD-L1 regulators to regulate PD-L1 stability during the immune process in many tumor cells [19, 20], and thus expected to be a new target for tumor immunotherapy. This evidence concerns the gene CMTM6 and neoplasm.